News - Pharmaphorum

Latest News

in News
Merck/Pfizer up the pressure on BMS in first-line kidney cancer
February 13, 2019 Share
X
Merck/Pfizer up the pressure on BMS in first-line kidney cancer
https://pharmaphorum.com/news/merck-pfizer-up-the-pressure-on-bms-in-first-line-kidney-cancer/
in News
Gilead NASH drug fails late stage trial
February 12, 2019 Share
X
Gilead NASH drug fails late stage trial
https://pharmaphorum.com/news/gilead-nash-drug-fails-late-stage-trial/

Scotland says no to Yescarta, but backs Kymriah

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types

Scotland says no to Yescarta, but backs Kymriah

https://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/

UCB joins with UK charity to research new epilepsy drugs

Belgium’s UCB has joined forces with the UK’s Epilepsy Society in a collaboration aimed at finding treatments for

UCB joins with UK charity to research new epilepsy drugs

https://pharmaphorum.com/news/ucb-joins-with-uk-charity-to-research-new-epilepsy-drugs/

Pharma companies clear the R&D decks in Q4

The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies’ pipelines as

Pharma companies clear the R&D decks in Q4

https://pharmaphorum.com/news/pharma-companies-clear-the-rd-decks-in-q4/

See all

More news

Alector kicks off biotech IPOs after US government shutdown

The 35-day US government shutdown has not just played havoc at government-run agencies – it has had a

Alector kicks off biotech IPOs after US government shutdown

https://pharmaphorum.com/news/alector-kicks-off-biotech-ipos-after-us-government-shutdown/

Gene therapy biotech shares sink on inconclusive trial results

Shares in two US gene therapy biotechs have fallen after two cutting-edge treatments failed to produce convincing results

Gene therapy biotech shares sink on inconclusive trial results

https://pharmaphorum.com/news/gene-therapy-biotech-shares-sink-on-inconclusive-trial-results/

AZ’s lung drug gets fast development in EU and US

Regulators in the US and Europe have fast-tracked development of AstraZeneca’s MEDI8897, an antibody drug aimed at preventing

AZ’s lung drug gets fast development in EU and US

https://pharmaphorum.com/news/us-and-eu-accelerate-medi8897/

Lilly scores with two Olumiant trials in atopic dermatitis

Eli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which

Lilly scores with two Olumiant trials in atopic dermatitis

https://pharmaphorum.com/news/lilly-scores-with-two-olumiant-trials-in-atopic-dermatitis/

Circassia prepares for potential US launch of nitric oxide product

UK biotech Circassia has said that its partner AIT Therapeutics has held a meeting with the FDA that

Circassia prepares for potential US launch of nitric oxide product

https://pharmaphorum.com/news/circassia-prepares-for-potential-us-launch-of-nitric-oxide-product/

Alkermes rebuffed by FDA on antidepressant

Alkermes is facing a significant delay for its ALKS 5461 candidate for major depressive disorder after the FDA

Alkermes rebuffed by FDA on antidepressant

https://pharmaphorum.com/news/alkermes-rebuffed-by-fda-on-antidepressant/

Insys opioid kickback trial takes a sordid turn

A former stripper who became a sales director for Insys Therapeutics has been accused of giving a lap

Insys opioid kickback trial takes a sordid turn

https://pharmaphorum.com/news/insys-opioid-kickback-trial-takes-a-sordid-turn/

Novartis spent $15bn on M&A last year, with more to come

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last

Novartis spent $15bn on M&A last year, with more to come

https://pharmaphorum.com/news/novartis-spent-15bn-on-ma-last-year-with-more-to-come/

Roche cancels two phase III Alzheimer’s trials

Roche and AC Immune have discontinued phase III trials of their Alzheimer’s disease drug crenezumab after an interim

Roche cancels two phase III Alzheimer’s trials

https://pharmaphorum.com/news/roche-cancels-two-phase-iii-alzheimers-trials/

Mixed results for non-opioid pain drug from Pfizer/Lilly

Pfizer and Eli Lilly have produced more phase 3 data that appear to back their non-opioid painkiller tanezumab.

Mixed results for non-opioid pain drug from Pfizer/Lilly

https://pharmaphorum.com/news/mixed-results-for-tanezumab/

Allergan abandons women’s health sale plan as profit slumps

Shares in Allergan fell after the company said it had swung to a loss in the last quarter

Allergan abandons women’s health sale plan as profit slumps

https://pharmaphorum.com/news/allergan-abandons-womens-health-sale-plan-as-profit-slumps/

AbbVie and J&J claim new Imbruvica okay in US

AbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL)

AbbVie and J&J claim new Imbruvica okay in US

https://pharmaphorum.com/news/abbvie-and-jj-claim-new-imbruvica-okay-in-us/

AbbVie wobbles as biosimilars bite Humira

AbbVie’s shares slipped ahead of the weekend when its fourth-quarter revenues missed forecasts, after biosimilar competition – particularly

AbbVie wobbles as biosimilars bite Humira

https://pharmaphorum.com/news/abbvie-wobbles-as-biosimilars-bite-humira/

Vertex licenses back CRISPR compounds from German Merck

US pharma Vertex has licensed back two gene editing compounds that can be used with CRISPR/Cas9 technology, from

Vertex licenses back CRISPR compounds from German Merck

https://pharmaphorum.com/news/vertex-licenses-back-crispr-compounds-from-german-merck/

Genentech brings back Alexander Hardy to take CEO position

Roche has filled the open CEO position at Genentech with Alexander Hardy, a veteran of the subsidiary. The

Genentech brings back Alexander Hardy to take CEO position

https://pharmaphorum.com/news/genentech-brings-back-alexander-hardy-ceo-position/

Search

Advanced Search

Trending

Latest News

More news